TWI631119B - 抗菌雙芳香族衍生物 - Google Patents

抗菌雙芳香族衍生物 Download PDF

Info

Publication number
TWI631119B
TWI631119B TW103113729A TW103113729A TWI631119B TW I631119 B TWI631119 B TW I631119B TW 103113729 A TW103113729 A TW 103113729A TW 103113729 A TW103113729 A TW 103113729A TW I631119 B TWI631119 B TW I631119B
Authority
TW
Taiwan
Prior art keywords
oxo
ethyl
pyrido
oxazin
methoxy
Prior art date
Application number
TW103113729A
Other languages
English (en)
Chinese (zh)
Other versions
TW201516043A (zh
Inventor
艾斯崔 福瑞德利
克利斯提安 赫許威倫
喬治 魯迪
柯奈利亞 宗布倫
席歐凡 克蘭
Original Assignee
愛杜西亞製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛杜西亞製藥有限公司 filed Critical 愛杜西亞製藥有限公司
Publication of TW201516043A publication Critical patent/TW201516043A/zh
Application granted granted Critical
Publication of TWI631119B publication Critical patent/TWI631119B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW103113729A 2013-04-16 2014-04-15 抗菌雙芳香族衍生物 TWI631119B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013053021 2013-04-16
??PCT/IB2013/053021 2013-04-16

Publications (2)

Publication Number Publication Date
TW201516043A TW201516043A (zh) 2015-05-01
TWI631119B true TWI631119B (zh) 2018-08-01

Family

ID=50639826

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103113729A TWI631119B (zh) 2013-04-16 2014-04-15 抗菌雙芳香族衍生物

Country Status (21)

Country Link
US (1) US9527867B2 (enExample)
EP (1) EP2986607B1 (enExample)
JP (1) JP6375365B2 (enExample)
KR (1) KR20150143720A (enExample)
CN (1) CN105143216B (enExample)
AR (1) AR095884A1 (enExample)
AU (1) AU2014255326B2 (enExample)
BR (1) BR112015026261A8 (enExample)
CA (1) CA2907832A1 (enExample)
CL (1) CL2015003019A1 (enExample)
EA (1) EA029361B1 (enExample)
ES (1) ES2640482T3 (enExample)
HK (1) HK1221459A1 (enExample)
MA (1) MA38588B1 (enExample)
MX (1) MX362338B (enExample)
PH (1) PH12015502411A1 (enExample)
PL (1) PL2986607T3 (enExample)
SA (1) SA515361261B1 (enExample)
SG (1) SG11201508479RA (enExample)
TW (1) TWI631119B (enExample)
WO (1) WO2014170821A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
AR102256A1 (es) * 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
UY36851A (es) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
TW201808906A (zh) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 作為殺蟲劑之經取代吡啶化合物
AR108108A1 (es) 2016-04-14 2018-07-18 Idorsia Pharmaceuticals Ltd Derivados biaromáticos antibacterianos con sustitución de oxetan-3-iloxi
GB2550437B (en) * 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
TW201833120A (zh) * 2017-02-17 2018-09-16 瑞士商愛杜西亞製藥有限公司 芳基噁唑啶酮抗生素化合物
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
CN111527093B (zh) * 2017-11-29 2023-06-09 巴格沃克斯研究有限公司 抗菌杂环化合物及其合成
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
EP4126855B1 (en) * 2020-03-24 2024-04-24 F. Hoffmann-La Roche AG Compounds and their use in the treatment of bacterial infections
CN115785718B (zh) * 2022-11-25 2023-08-22 四川大学 一种多基底表面的金属配位抗菌涂层及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126024A2 (en) * 2007-04-11 2008-10-23 Actelion Pharmaceuticals Ltd Oxazolidinone antibiotic derivatives
WO2010015985A1 (en) * 2008-08-04 2010-02-11 Actelion Pharmaceuticals Ltd Tricyclic alkylaminomethyloxazolidinone derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297042A1 (de) 1987-06-23 1988-12-28 Ciba-Geigy Ag Substituierte Penem-Verbindungen
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
AU1026901A (en) 1999-10-29 2001-05-08 Syngenta Participations Ag Novel herbicides
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP2141154A4 (en) 2007-03-30 2011-06-01 Inst Med Molecular Design Inc OXAZOLIDINONE DERIVATIVITY WITH HEMMETIC EFFECT ON TYPE I 11-HYDROXYSTEROIDDEHYDROGENASE
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
BRPI0907892A2 (pt) 2008-02-20 2015-07-28 Actelion Pharmaceuticals Ltd Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
CA2713187C (en) 2008-02-22 2016-06-07 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
ES2395491T3 (es) 2008-10-10 2013-02-13 Actelion Pharmaceuticals Ltd. 2-Benzotiofenil y 2-naftil-oxazolidinonas y sus análogos azaisósteros como agentes antibacterianos
IN2014CN04126A (enExample) 2011-11-08 2015-07-10 Actelion Pharmaceuticals Ltd

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126024A2 (en) * 2007-04-11 2008-10-23 Actelion Pharmaceuticals Ltd Oxazolidinone antibiotic derivatives
WO2010015985A1 (en) * 2008-08-04 2010-02-11 Actelion Pharmaceuticals Ltd Tricyclic alkylaminomethyloxazolidinone derivatives

Also Published As

Publication number Publication date
MA38588B1 (fr) 2018-04-30
KR20150143720A (ko) 2015-12-23
EP2986607B1 (en) 2017-06-14
BR112015026261A2 (pt) 2017-07-25
WO2014170821A1 (en) 2014-10-23
PL2986607T3 (pl) 2017-11-30
US20160075722A1 (en) 2016-03-17
AR095884A1 (es) 2015-11-18
TW201516043A (zh) 2015-05-01
EA029361B1 (ru) 2018-03-30
EP2986607A1 (en) 2016-02-24
AU2014255326B2 (en) 2018-09-13
EA201501025A1 (ru) 2016-08-31
SA515361261B1 (ar) 2016-06-15
ES2640482T3 (es) 2017-11-03
MX2015014576A (es) 2016-03-04
JP6375365B2 (ja) 2018-08-15
BR112015026261A8 (pt) 2017-12-26
PH12015502411A1 (en) 2016-02-22
MX362338B (es) 2019-01-11
JP2016516805A (ja) 2016-06-09
US9527867B2 (en) 2016-12-27
SG11201508479RA (en) 2015-11-27
AU2014255326A1 (en) 2015-11-26
MA38588A1 (fr) 2017-05-31
CN105143216B (zh) 2018-04-13
CN105143216A (zh) 2015-12-09
CA2907832A1 (en) 2014-10-23
HK1221459A1 (zh) 2017-06-02
CL2015003019A1 (es) 2016-09-30

Similar Documents

Publication Publication Date Title
CN105143216B (zh) 抗菌双芳香族衍生物
KR102460385B1 (ko) 비시클릭 헤테로아릴 치환된 화합물
CN111909131B (zh) Erbb/btk抑制剂
US11124486B2 (en) 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same
CN110214136A (zh) 作为malt1抑制剂的吡唑衍生物
KR20210124296A (ko) 면역조절제, 조성물 및 이의 방법
JP2021526551A (ja) キナーゼ阻害剤としてのヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びそれらを使用する方法
WO2001030757A1 (en) Drug discharge pump inhibitors
CN107108601A (zh) 糖苷酶抑制剂
CA2934216A1 (en) Substitued phenyl or benzyl propanote derivatives and pharmaceutical compositiions thereof useful as nrf2 regulators
JP2010527951A (ja) キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体
JP2014525396A (ja) キナゾリン−2,4−ジオン誘導体
WO2015057626A1 (en) QUINOLINYL MODULATORS OF RORyT
JP2017531008A (ja) 抗菌活性を有するアミノアルコキシ置換された塩基性二芳香族誘導体
JP2025537254A (ja) グルカゴン様ペプチド1受容体アゴニスト
EP3057951A1 (en) Methylene linked quinolinyl modulators of ror-gamma-t
CN103261176A (zh) 1,4-氧杂氮杂环庚烷衍生物
JP2014526550A (ja) フェニルイミドを含むベンゾチアゾール誘導体またはその塩及びそれを含む医薬組成物
JP2006182648A (ja) 7員複素環誘導体
TW201429972A (zh) 抗菌噁唑酮衍生物
KR20150105302A (ko) 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
TW201429973A (zh) 抗菌噁二唑酮衍生物
CN108884088A (zh) 具有环氧丙烷-3-基氧基取代的抗菌双芳香族衍生物
JP2025502036A (ja) ベンゾチアゾール類似体および抗結核薬のブースターとしてのその使用
WO2024249252A1 (en) Methods of using apol1 inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees